A new expert review in Alzheimer’s & Dementia argues that smartphones, smartwatches, and unobtrusive home sensors could help detect frontotemporal degeneration (FTD) earlier, track symptoms more precisely, and make clinical trials more inclusive—if developers meet high bars for validation, privacy, and usability.
Why it matters
FTD is a rare brain disease that can disrupt language, behavior, movement, and speech. There are no approved treatments that slow the disease, and traditional clinic-based tests often miss subtle changes or place heavy burdens on families. Digital health technologies (DHTs)—from speech-analysis apps to passive motion sensors—can capture everyday changes in how people speak, move, socialize, and complete tasks, sometimes earlier than standard measures.
What the review found
- Promising tools are already being tested. Remote smartphone cognitive tests for FTD have proved feasible and reliable in recent studies, supporting their use alongside in‑person assessments.
- Home is the new exam room. Continuous, home‑based monitoring of movement and daily routines has been linked to smaller sample sizes needed in trials—because high‑frequency data can reveal change sooner and more consistently.
- Speech may be a powerful digital biomarker. Open repositories such as TalkBank/DementiaBank are accelerating speech‑analysis research by standardizing tasks and sharing high‑quality audio for method comparisons and algorithm development.
The bottlenecks
Despite rapid progress, regulatory acceptance is still limited. In the United States, no DHT has advanced beyond the first step of the FDA’s formal qualification pathway for biomarkers or outcome measures; in Europe, the EMA only recently approved its first DHT as a primary endpoint—in Duchenne muscular dystrophy—showing the bar can be met but remains high.
Beyond regulation, the authors highlight practical hurdles: build tools that patients and caregivers can actually use; earn trust in communities under‑represented in research; support clinicians with clear, low‑burden data views; and protect sensitive information (especially voice and genetic data) under HIPAA/GDPR‑aligned practices. They also call for shared data standards and better “metadata” so multi‑site studies can compare results reliably as devices and software evolve.
A roadmap for getting to impact
The paper lays out a development path for “fit‑for‑purpose” digital measures in FTD: start with the end‑user experience; follow verification–analytical validation–clinical validation steps; lean on existing FDA/EMA programs (for example, the FDA’s ISTAND pilot) that can guide teams early; and borrow playbooks from Parkinson’s disease and other fields where smartwatch‑ and app‑based measures are further along.
The Nano Take
Digital tools won’t replace neurologists, but they can fill a crucial gap: capturing real‑life function between clinic visits. If developers can prove accuracy, protect privacy, and reduce burden for families, these technologies could speed up trials and, ultimately, enable more timely, tailored care for people living with—or at risk for—FTD.
Source: Nevler N, Niehoff D, Gleixner AM, et al. “Developing digital health technologies for frontotemporal degeneration,” Alzheimer’s & Dementia, 2025.